This is a working overview of storage stability, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-13 and is reviewed periodically as new material appears.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
=== Turkey === The first therapies in Turkey using 177Lu-DOTATATE PRRT were carried out in early 2014, for treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) at the Istanbul University-Cerrahpaşa.
Portugal's main import markets in 2026 were Spain at 32.9% and Germany at 11.9%. Portugal's main imports are machinery and mechanical appliances, chemical products, agricultural products, and mineral fuels. Since the 1990s, Portugal's economic model has been based on public consumption and economic development focused on exports, private investment and the development of its high-tech sector. Consequently, business services have overtaken more traditional industries such as wine and cork in export earnings. Operated by the Euronext Lisbon, Portugal's stock market, the PSI, includes 16 major companies based on the country, including Sonae, Mota-Engil, Corticeira Amorim, The Navigator Company, and EDP. In 2025, Portugal ranked 16th among European Union member states in innovation by the European Innovation Scoreboard, while placing 31st worldwide in the Global Innovation Index. In 2024, neuroscience accounted for 12.5% of Portugal's scientific output, the second-highest national share, and the country ranked 23rd worldwide in total neuroscience output. Among the research institutions based in the country are the Gulbenkian Institute of Molecular Medicine, the International Iberian Nanotechnology Laboratory, and the Champalimaud Foundation which was the world's 11th top non-profit institution in neuroscience research between 2019 and 2023.
=== Reduction factor === Reduction factor (RF) for a virus removal or inactivation step is calculated using the following equation: RFstep = log10 [(V1 x T1)/(V2 x T2)] Where: V1 = volume of spiked feedstock prior to the clearance step; T1 = virus concentration of spiked feedstock prior to the clearance step; V2 = volume of material after the clearance step; and T2 = virus concentration of material after the clearance step. The reduction factor needed for a certain process stream is dependent on many different factors, some of which include:
In April 2021, Valve abandoned efforts to reboot the project, saying it had not found enough interested players to justify development. In June 2019, Valve released its second-generation VR hardware, the Valve Index. They also released Dota Underlords into early access, an auto battler based on a Dota 2 community-created mode Dota Auto Chess. In March 2020, Valve released Half-Life: Alyx, a VR game. It received acclaim and was described as VR's first killer app. Newell said in January 2021 that the success of Alyx created desire within the company to develop more games, and that several were under development. Valve collaborated with Netflix for Dota: Dragon's Blood, an animated television series based on Dota, which premiered in March 2021. In February 2022, Valve released the Steam Deck, a portable game system that runs on Linux-based SteamOS with the Proton compatibility layer that allows most Windows games on Steam to run on Linux without modification. In September 2023, Valve released Counter-Strike 2. It received generally favorable reviews, but player reception was mixed. In 2024, Valve began beta-testing a new multiplayer game, Deadlock, a combination of a hero shooter and MOBA. In September, staff members from Hopoo Games, developers of Risk of Rain, announced that they had been employed at Valve. According to a report by Forbes Australia published in December 2024, Valve had an annual revenue of $5 billion by 2023, with a 40% profit margin. Steam accounted for around 60% of this revenue, double that of 2019.
=== Nitrite test === The nitrite test is commonly used to diagnose urinary tract infections by measuring the concentrations of nitrite in solution, indicating the presence of a gram-negative organism. A simple nitrite test can be performed by adding 4 M sulfuric acid to the sample until acidic, and then adding 0.1 M iron (II) sulfate to the solution. A positive test for nitrite is indicated by a dark brown solution, arising from the iron-nitric oxide complex ion.
Sources: en.wikipedia.org
Two pathways for PLP are currently known: one requires deoxyxylulose 5-phosphate (DXP), while the other does not, hence they are known as DXP-dependent and DXP-independent. These pathways have been studied extensively in Escherichia coli and Bacillus subtilis, respectively. Despite the disparity in the starting compounds and the different number of steps required, the two pathways possess many commonalities. The DXP-dependent pathway:
== Safety == Inhalation of n-hexane at 5000 ppm for 10 minutes produces marked vertigo; 2500-1000 ppm for 12 hours produces drowsiness, fatigue, loss of appetite, and paresthesia in the distal extremities; 2500–5000 ppm produces muscle weakness, cold pulsation in the extremities, blurred vision, headache, and anorexia. Chronic occupational exposure to elevated levels of n-hexane has been demonstrated to be associated with peripheral neuropathy in auto mechanics in the US, and neurotoxicity in workers in printing presses, and shoe and furniture factories in Asia, Europe, and North America. The US National Institute for Occupational Safety and Health (NIOSH) has set a recommended exposure limit (REL) for hexane isomers (not n-hexane) of 100 ppm (350 mg/m3 (0.15 gr/cu ft)) over an 8-hour workday. However, for n-hexane, the current NIOSH REL is 50 ppm (180 mg/m3 (0.079 gr/cu ft)) over an 8-hour workday. This limit was proposed as a permissible exposure limit (PEL) by the Occupational Safety and Health Administration in 1989; however, this PEL was overruled in US courts in 1992. The current n-hexane PEL in the US is 500 ppm (1,800 mg/m3 (0.79 gr/cu ft)). Hexane and other volatile hydrocarbons (petroleum ether) present an aspiration risk. n-Hexane is sometimes used as a denaturant for alcohol, and as a cleaning agent in the textile, furniture, and leather industries. It is slowly being replaced with other solvents. Like gasoline, hexane is highly volatile and is an explosion risk.
It is also used to treat myxedema coma, which is a severe form of hypothyroidism characterized by mental status changes and hypothermia. As it is a medical emergency with a high mortality rate, it should be treated in the intensive-care unit with thyroid hormone replacement and aggressive management of individual organ system complications.
Elizabeth Broadbent; Keith J Petrie; Jodie Main; John Weinman (2006). "The brief illness perception questionnaire". Journal of Psychosomatic Research. 60 (6): 631–637. doi:10.1016/j.jpsychores.2005.10.020. PMID 16731240. Wikidata Q50936509. Elizabeth Broadbent; Carissa Wilkes; Heidi Koschwanez; John Weinman; Sam Norton; Keith J Petrie (2015). "A systematic review and meta-analysis of the Brief Illness Perception Questionnaire". Psychology & Health. 30 (11): 1361–1385. doi:10.1080/08870446.2015.1070851. PMID 26181764. Wikidata Q38548518. E. Broadbent; R. Stafford; B. MacDonald (2009). "Acceptance of Healthcare Robots for the Older Population: Review and Future Directions". International journal of social robotics. 1 (4): 319–330. doi:10.1007/s12369-009-0030-6. Wikidata Q115258302. Hayley Robinson; Bruce Macdonald; Ngaire Kerse; Elizabeth Broadbent (2013). "The psychosocial effects of a companion robot: a randomized controlled trial". Journal of the American Medical Directors Association. 14 (9): 661–667. doi:10.1016/j.jamda.2013.02.007. PMID 23545466. Wikidata Q45166572. Elizabeth Broadbent; Liesje Donkin; Julia C Stroh (2011). "Illness and treatment perceptions are associated with adherence to medications, diet, and exercise in diabetic patients". Diabetes Care. 34 (2): 338–340. doi:10.2337/dc10-1779. PMC 3024345. PMID 21270191. Wikidata Q34507111.
Sources: en.wikipedia.org
==== Newsreel tradition ==== The newsreel tradition is important in documentary film. Newsreels at this time were sometimes staged but usually re-enactments of events that had already happened, not attempts to steer events as they were happening. For instance, much of the battle footage from the early 20th century was staged; the cameramen would usually arrive on site after a major battle and re-enact scenes to film them.
A&W also sells their Mozza Burger, which is not part of the burger family nor the value menu. It consists of a beef patty, lettuce, tomato, bacon, mozzarella cheese, and their special Mozza sauce on a sesame seed bun. Discontinued offerings include Bone-in Chubby Chicken (sold in 2-3 piece combos, buckets of 10, with a "family box" of fries/onion rings, and a side of potato salad/coleslaw (also discontinued options)), discontinued members of the Burger Family: Grandma Burger, a prime rib burger topped with caramelized onions and horseradish sauce; and the Sirloin Burger Twins, which were a pair of sliders, the Veggie Deluxe (veggie burger with mozzarella cheese, lettuce, tomato, onion, and pickles), traditional hot dogs, and the Whistle Dog (topped with cheese and bacon). The ketchup and mustard served at A&W location are processed by French's at their Ontario facility and use only Canadian ingredients. The Whistle Dog, a hot dog dressed with cheese, bacon and relish, was available in Canada, but was discontinued at the end of 2016; the regular hot dog was similarly discontinued. In July 2022, all Canadian A&W locations brought back the Whistle Dog for a limited time.
=== Dependence and withdrawal === Dextromethorphan is considered less addictive than other common cough suppressants, such as the opiate codeine. Since it acts as a serotonin reuptake inhibitor, users report that regular recreational use over a long period of time can cause withdrawal symptoms similar to those of antidepressant discontinuation syndrome. Additionally, disturbances have been reported in sleep, senses, movement, mood, and thinking.
In November 2004, club doctor Riccardo Agricola was given a 22-month prison sentence and fined €2,000 for sporting fraud by providing performance-enhancing drugs, specifically EPO, to players between 1994 and 1998, Leading hematologist Giuseppe d'Onofrio said that it was "practically certain" that midfielders Antonio Conte and Alessio Tacchinardi had taken EPO to overcome brief bouts of anemia, and that it was "very probable" that seven other players – Alessandro Birindelli, Alessandro Del Piero, Didier Deschamps, Dimas, Paolo Montero, Gianluca Pessotto and Moreno Torricelli – had taken EPO in small doses. In April 2005, the Court of Arbitration for Sport gave the following advisory opinion, in part: "The use of pharmaceutical substances which are not expressly prohibited by sports law, and which cannot be considered as substances similar or related to those expressly prohibited, is not to be sanctioned by disciplinary measures. However, regardless of the existence or not of any judgement rendered by a State court, sports authorities are under the obligation to prosecute the use of pharmaceutical substances which are prohibited by sports law or any other anti-doping rule violation in order to adopt disciplinary measures." In December 2005, Agricola was acquitted of the charges by Turin's court of appeal.
=== Transportation === On April 10, 2019, Premier Ford and Minister Yurek announced Ontario's transit plan for the Greater Toronto Area (GTA)—one of the largest metropolitan areas in Canada. The $30 billion dollar project would include the $10.9 billion Ontario Line, the $5.5 billion Scarborough subway extension, the $5.6 billion Yonge North subway extension to Richmond Hill, and the $4.7 billion Eglinton West extension. The province would provide $11.2 billion in funding and "wants to own the lines but leave the city and TTC to operate the subway system." Premier Ford said, "We are making the biggest and largest investment in new subways in Canadian history." The City of Toronto had already spent $224 million of public money on its own "planning and design of transit infrastructure in Toronto." The City raised concerns about delays considering the city manager—Chris Murray's "sweeping" April 16 transit expansion report, "which also suggests several projects may now be in limbo, including two Scarborough transit lines and Mayor John Tory's signature SmartTrack plan." In a December 13, 2018, City Council meeting, Toronto Transit Commission (TTC) CEO Rick Leary, said that he had not had any "direct negotiations or discussion" with the province on what "it would look like if the province uploaded the subway system"—bringing the "TTC's subway system under provincial ownership". While there were clear financial benefits to the city, the council voted to "reaffirm their desire to keep the entire TTC — subways and all" and requested more clarity from the province.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.